French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)
1 other identifier
observational
5,000
1 country
36
Brief Summary
This study is a registry including prospective and retrospective data on all patients who have been presented in a Multidisciplinary tumor board or RCP to be eligible for CAR-T cell treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2019
Longer than P75 for all trials
36 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 19, 2019
CompletedFirst Submitted
Initial submission to the registry
March 27, 2020
CompletedFirst Posted
Study publicly available on registry
March 31, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 19, 2038
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 19, 2038
March 4, 2026
March 1, 2026
19 years
March 27, 2020
March 2, 2026
Conditions
Outcome Measures
Primary Outcomes (6)
overall survival from eligibility
15 years
Overall survival from administration
15 years
complete response rate
15 years
Progression free survival
15 years
Duration of response
15 years
Delays between patient eligibility and CAR-T treatment
15 years
Eligibility Criteria
Patient eligible for a treatment with CAR-T for an hematological malignancy
You may qualify if:
- Patient treated with CAR-T from 1 July 2018 under temporary authorization (ATU) or covered by French health insurance system (under post-ATU or MA) in a qualified center before activation of this register in this center
- If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive
- Patient eligible for a treatment with CAR-T for an hematological malignancy which is covered by French health insurance (for ATUs / post-ATUs or MA), or as part of a clinical trial with the same indication, after the activation of this register in this center.
- Patient whose CAR-T indication has been validated during a multidisciplinary tumor board (RCP) of a qualified center, according to the ministerial order of 8 August 2019
- Patient deemed eligible for a treatment with CAR-T after a medical exam performed in a qualified center according to the ministerial order of 8 August 2019
- If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- The Lymphoma Academic Research Organisationlead
- Gilead Sciencescollaborator
- Novartiscollaborator
- Bristol-Myers Squibbcollaborator
Study Sites (36)
CHU d'Amiens - Hôpital Sud
Amiens, France
CHU Angers
Angers, France
CHRU Besançon - Hôpital Minjoz
Besançon, France
CHU de Brest - Hôpital du Morvan
Brest, France
Institut d'Hématologie de Basse Normandie
Caen, France
CHU d'Estaing
Clermont-Ferrand, France
APHP - Hôpital Henri Mondor
Créteil, France
CHU de Dijon
Dijon, France
CHU de Grenoble
La Tronche, France
CHRU de Lille - Hôpital Claude Hurriez
Lille, France
Hôpital Dupuytren
Limoges, France
Centre Léon Bérard
Lyon, France
Institut d'Hématologie et d'Oncologie Pédiatrique (IHOP)
Lyon, France
Hôpital de la Timone
Marseille, France
Institut Paoli Calmette
Marseille, France
CHU de Montpellier
Montpellier, France
CHU de Nantes - Hôtel Dieu
Nantes, France
CHU de Nice
Nice, France
APHP - Hôpital Cochin
Paris, France
APHP - Hôpital La Pitié Salpêtrière
Paris, France
APHP - Hôpital Necker
Paris, France
APHP - Hôpital Saint Antoine
Paris, France
APHP - Hôpital Saint Louis
Paris, France
APHP - Hôpital Universitaire Robert Debré
Paris, France
Centre Francois Magendie
Pessac, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Hôpital de la Milétrie - CHU de Poitiers
Poitiers, France
CHU de Rennes - Hôpital Pontchaillou
Rennes, France
Centre Henri Becquerel
Rouen, France
CHU de Rouen Normandie
Rouen, France
Institut de Cancérologie Hématologie Universitaire de Saint Etienne
Saint-Priest-en-Jarez, France
ICANS (Institut de Cancérologie Strasbourg Europe)
Strasbourg, France
Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O)
Toulouse, France
CHU Bretonneau
Tours, France
CHU Brabois
Vandœuvre-lès-Nancy, France
Gustave Roussy Cancer Campus
Villejuif, France
Related Publications (3)
Cayla S, Karlin L, Lambert J, Lazareth A, Talbot A, Mohty M, Malard F, Petillon MO, Manier S, Yakoub-Agha I, Caillot D, Lafon I, Leleu X, Moya N, Royer B, Schiano De Colella JM, Brisou G, Touzeau C, Perrot A, Bories P, Vincent L, Guedon H, Decaux O, Ferment B, Houot R, Le Gouill S, Bigot N, Facon T, Corre J, Avet-Loiseau H, Moreau P, Arnulf B. Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study. Blood Adv. 2026 Feb 24;10(4):1324-1333. doi: 10.1182/bloodadvances.2025017597.
PMID: 40966637DERIVEDSesques P, Kirkwood AA, Kwon M, Rejeski K, Jain MD, Di Blasi R, Brisou G, Gros FX, le Bras F, Bories P, Choquet S, Rubio MT, Iacoboni G, O'Reilly M, Casasnovas RO, Bay JO, Mohty M, Joris M, Abraham J, Castilla Llorente C, Loschi M, Carras S, Chauchet A, La Rochelle LD, Hermine O, Guidez S, Cony-Makhoul P, Fogarty P, Le Gouill S, Morschhauser F, Gastinne T, Cartron G, Subklewe M, Locke FL, Sanderson R, Barba P, Houot R, Bachy E. Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma. J Hematol Oncol. 2024 Aug 6;17(1):61. doi: 10.1186/s13045-024-01579-w.
PMID: 39107847DERIVEDBachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, Beauvais D, Roulin L, Gros FX, Rubio MT, Bories P, Bay JO, Llorente CC, Choquet S, Casasnovas RO, Mohty M, Guidez S, Joris M, Loschi M, Carras S, Abraham J, Chauchet A, Drieu La Rochelle L, Deau-Fischer B, Hermine O, Gastinne T, Tudesq JJ, Gat E, Broussais F, Thieblemont C, Houot R, Morschhauser F. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022 Oct;28(10):2145-2154. doi: 10.1038/s41591-022-01969-y. Epub 2022 Sep 22.
PMID: 36138152DERIVED
Study Officials
- PRINCIPAL INVESTIGATOR
Steven LE GOUILL, Pr
Institut Curie
- PRINCIPAL INVESTIGATOR
Roch HOUOT, Pr
CHU Pontchaillou
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 15 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 27, 2020
First Posted
March 31, 2020
Study Start
December 19, 2019
Primary Completion (Estimated)
December 19, 2038
Study Completion (Estimated)
December 19, 2038
Last Updated
March 4, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will not share